Taysha Gene Therapies (NASDAQ:TSHA) Posts Quarterly Earnings Results, Misses Estimates By $0.02 EPS

Taysha Gene Therapies (NASDAQ:TSHA) announced its earnings results on Tuesday. The company reported ($0.13) earnings per share for the quarter, missing the consensus estimate of ($0.11) by ($0.02), Zacks reports.

Taysha Gene Therapies Stock Up 5.3%

NASDAQ TSHA traded up $0.34 during trading hours on Tuesday, reaching $6.71. 2,906,729 shares of the company traded hands, compared to its average volume of 2,868,341. The stock has a market capitalization of $1.93 billion, a PE ratio of -17.65 and a beta of 1.22. The company has a current ratio of 14.04, a quick ratio of 14.04 and a debt-to-equity ratio of 0.23. Taysha Gene Therapies has a 12 month low of $2.69 and a 12 month high of $7.30. The company has a 50 day moving average of $6.06 and a two-hundred day moving average of $5.45.

Insider Buying and Selling at Taysha Gene Therapies

In other news, insider Sukumar Nagendran sold 200,000 shares of the company’s stock in a transaction dated Friday, July 10th. The shares were sold at an average price of $6.24, for a total value of $1,248,000.00. Following the sale, the insider owned 936,410 shares in the company, valued at approximately $5,843,198.40. This represents a 17.60% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders own 3.48% of the company’s stock.

Institutional Trading of Taysha Gene Therapies

Several hedge funds and other institutional investors have recently bought and sold shares of the company. Marex Group plc bought a new position in Taysha Gene Therapies during the 2nd quarter worth approximately $29,000. E Fund Management Co. Ltd. acquired a new stake in shares of Taysha Gene Therapies during the 2nd quarter valued at approximately $31,000. Tower Research Capital LLC TRC raised its position in shares of Taysha Gene Therapies by 156.5% during the 2nd quarter. Tower Research Capital LLC TRC now owns 17,606 shares of the company’s stock valued at $41,000 after acquiring an additional 10,742 shares in the last quarter. BNP Paribas Financial Markets lifted its stake in Taysha Gene Therapies by 51.9% during the second quarter. BNP Paribas Financial Markets now owns 18,591 shares of the company’s stock worth $43,000 after purchasing an additional 6,350 shares during the last quarter. Finally, Caitong International Asset Management Co. Ltd lifted its stake in Taysha Gene Therapies by 143.8% during the fourth quarter. Caitong International Asset Management Co. Ltd now owns 7,811 shares of the company’s stock worth $43,000 after purchasing an additional 4,607 shares during the last quarter. 77.70% of the stock is owned by institutional investors.

Analyst Ratings Changes

A number of equities analysts have commented on TSHA shares. Weiss Ratings reiterated a “sell (d-)” rating on shares of Taysha Gene Therapies in a report on Wednesday, June 24th. Wall Street Zen downgraded Taysha Gene Therapies from a “hold” rating to a “sell” rating in a research note on Saturday, May 9th. The Goldman Sachs Group lifted their target price on Taysha Gene Therapies from $11.00 to $13.00 and gave the stock a “buy” rating in a research report on Tuesday, July 21st. Citigroup reissued an “outperform” rating on shares of Taysha Gene Therapies in a report on Tuesday, June 23rd. Finally, Needham & Company LLC restated a “buy” rating and set a $12.00 price objective on shares of Taysha Gene Therapies in a research note on Tuesday, June 30th. Two investment analysts have rated the stock with a Strong Buy rating, eleven have assigned a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, Taysha Gene Therapies presently has an average rating of “Buy” and an average target price of $12.77.

About Taysha Gene Therapies

Taysha Gene Therapies, Inc (NASDAQ: TSHA) is a clinical-stage biotechnology company focused on developing gene therapies for rare monogenic diseases of the central nervous system. Using a proprietary adeno-associated viral (AAV) vector platform, the company engineers novel capsids and regulatory elements to optimize delivery and expression of therapeutic genes. Its pipeline features lead programs such as TSHA-102 for GM2 gangliosidoses (Tay–Sachs and Sandhoff diseases), TSHA-101 for GM1 gangliosidosis and TSHA-103 for aromatic l-amino acid decarboxylase (AADC) deficiency, alongside earlier-stage candidates targeting other life-threatening pediatric CNS disorders.

Founded in 2019 and headquartered in Dallas, Texas, Taysha Gene Therapies completed its initial public offering in May 2021.